```html

Exanthematous Drug Eruption – Comprehensive Medical Guide

Overview

Exanthematous drug eruption (also called morbilliform drug eruption) is the most common type of adverse cutaneous drug reaction. It appears as a widespread, symmetric, erythematous (red) maculopapular rash that typically starts on the trunk and spreads to the limbs. The eruption resembles that of measles (“morbilli”), hence the term “morbilliform.”

Who it affects: Almost anyone can develop an exanthematous drug eruption, but certain groups are more frequently impacted:

• Adults — particularly women, who account for ~60% of reported cases.
• Children and adolescents, especially those receiving antibiotics.
• Patients with a history of drug allergies or multiple drug exposures.

Prevalence: Cutaneous drug eruptions account for 2–3% of all hospital admissions for skin disorders, and exanthematous eruptions compose roughly 70–80% of these cases [1] CDC, 2023. In the United States, an estimated 5–7% of the population will experience a drug‑induced rash at some point in their lives [2] NIH, 2022.

Symptoms

The presentation can vary widely, but the classic pattern includes the following features:

Skin Findings

• Maculopapular rash: Flat red patches (macules) studded with raised bumps (papules). Often described as “sandpaper‑like.”
• Symmetry: Rash is usually bilateral and mirrors on both sides of the body.
• Distribution: Begins on the trunk (chest, abdomen, back) and spreads to the neck, arms, and sometimes the face. Palms, soles, and mucous membranes are typically spared (except in severe cases).
• Timing: Appears 4–14 days after the offending drug is started, but can occur sooner if there has been prior sensitization.
• Itchiness (pruritus): Most patients experience mild to moderate itching.
• Scaling: After 5–7 days, lesions may become dry and peel as they resolve.

Systemic Symptoms (less common)

• Fever (usually low‑grade)
• Fatigue or malaise
• Headache
• Joint or muscle aches

Red‑flag features that suggest a more severe reaction

• Rapid spread with target‑like lesions → consider Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
• Fever > 38.5 °C, facial swelling, or involvement of mucous membranes.
• Severe itching, swelling, or urticaria indicating a possible urticarial or anaphylactic component.

Causes and Risk Factors

Exanthematous drug eruptions are immune‑mediated hypersensitivity reactions, most often Type IV (delayed, T‑cell mediated). The offending agents act as haptens, binding to skin proteins and triggering an immune response.

Common Culprit Medications

• Antibiotics: β‑lactams (penicillins, cephalosporins), sulfonamides, tetracyclines, and fluoroquinolones.
• Antiepileptics: Phenytoin, carbamazepine, lamotrigine.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): ibuprofen, naproxen.
• Allopurinol.
• Antiretrovirals, antihypertensives, and sulfonylureas.

Risk Factors

• Previous drug allergy or rash.
• Polypharmacy – taking several new medications simultaneously.
• Genetic predisposition (e.g., HLA‑B*57:01 associated with abacavir rash).
• Impaired renal or hepatic function, which can increase drug levels.
• Viral infections (e.g., Epstein‑Barr virus) that may prime the immune system.
• Age — children and elderly patients have higher incidence due to higher prescription rates.

Diagnosis

Diagnosis is primarily clinical, supported by a thorough medication history and exclusion of other causes.

Step‑by‑step approach

1. History taking: Document all prescription, OTC, and herbal products taken in the previous 4 weeks. Note the start date, dosage, and any previous reactions.
2. Physical examination: Assess rash morphology, distribution, and presence of systemic signs.
3. Rule out mimickers: Viral exanthems, autoimmune diseases (e.g., lupus), psoriasis, and contact dermatitis.

Laboratory & Diagnostic Tests

• Complete blood count (CBC): May show eosinophilia, especially in drug reactions.
• Liver function tests (LFTs) & renal panel: Baseline for monitoring, as some eruptions are associated with organ involvement.
• Patch testing: Performed 4–6 weeks after resolution to identify the culprit drug; sensitivity ~70% for certain agents [3] Mayo Clinic, 2022.
• Skin biopsy: Reserved for atypical presentations; histology typically shows a superficial perivascular lymphocytic infiltrate with eosinophils.

Treatment Options

Treatment focuses on stopping the offending drug, relieving symptoms, and preventing complications.

Immediate Measures

1. Discontinue the suspected drug: If multiple agents are possible, stop all non‑essential medications.
2. Substitute if needed: Use an alternative class (e.g., a macrolide antibiotic if a β‑lactam is implicated).

Pharmacologic Therapies

• Topical corticosteroids: Low‑ to medium‑potency (hydrocortisone 1% or triamcinolone 0.1%) applied twice daily to reduce inflammation and itching.
• Systemic corticosteroids: Prednisone 0.5 mg/kg/day for 5–7 days may be considered for extensive or symptomatic rashes, but routine use is controversial because most exanthematous eruptions resolve spontaneously.
• Antihistamines: Non‑sedating agents (cetirizine, loratadine) for pruritus; sedating options (diphenhydramine) at night if sleep is disturbed.
• Emollients & barrier creams: Moisturizers containing ceramides or colloidal oatmeal help restore skin integrity.

Supportive Care

• Cool compresses to soothe burning sensations.
• Adequate hydration – 2–3 L of water daily unless contraindicated.
• Avoid hot showers, harsh soaps, and tight clothing that can aggravate the rash.

When to Consider Specialty Referral

• Unclear etiology after initial work‑up.
• Rapid progression, bullae formation, or mucosal involvement.
• Suspected severe cutaneous adverse reactions (SCARs) such as SJS/TEN.

Living with Exanthematous Drug Eruption

Although most eruptions are self‑limited, they can be uncomfortable and affect quality of life. Below are practical tips for daily management.

Skin Care Routine

• Use mild, fragrance‑free cleansers (e.g., Cetaphil or Dove Sensitive).
• Pat skin dry; avoid rubbing.
• Apply moisturizers within 3 minutes of bathing to lock in moisture.
• Wear cotton or soft bamboo fabrics; avoid wool or synthetic blends that may irritate.

Symptom Relief

• Take antihistamines at the same time each day for consistent control.
• Apply cool (not ice‑cold) wet compresses for 10–15 minutes, 3–4 times daily.
• Use over‑the‑counter (OTC) analgesics such as acetaminophen for mild fever or aches—avoid NSAIDs if they were the suspected trigger.

Monitoring & Follow‑up

• Track rash evolution with photographs or a journal.
• Schedule a follow‑up visit within 1–2 weeks after drug discontinuation to ensure resolution.
• Report any new symptoms (e.g., blistering, swelling of lips) immediately.

Psychosocial Aspects

• Rash visibility can cause anxiety; discuss concerns with a healthcare provider.
• Support groups (online forums, patient advocacy sites) can provide reassurance.
• Consider counseling if the eruption triggers significant stress or depression.

Prevention

While not all drug eruptions can be avoided, risk can be substantially reduced through careful prescribing and patient education.

For Patients

• Maintain an up‑to‑date medication list, including supplements.
• Inform every prescriber of any known drug allergies.
• Ask about alternative medications if you have a history of rash with a specific drug class.
• Avoid self‑medicating with antibiotics or NSAIDs without medical guidance.

For Healthcare Providers

• Review allergy history before prescribing high‑risk drugs (e.g., sulfonamides, antiepileptics).
• Start with the lowest effective dose and consider step‑wise escalation.
• Educate patients on early signs of rash and when to call.
• Document any adverse reactions in the electronic health record to prevent re‑exposure.

Complications

Most exanthematous drug eruptions resolve without sequelae, but complications can arise, especially when the reaction is misidentified or treatment is delayed.

• Secondary bacterial infection: Scratching can breach the skin barrier, leading to impetigo or cellulitis.
• Persistent hyperpigmentation: Post‑inflammatory changes may leave dark spots, particularly in darker skin types.
• Progression to severe cutaneous adverse reactions (SCARs): Approximately 0.1–0.5% of maculopapular drug eruptions evolve into SJS/TEN, which carry mortality rates of 10–30% [4] WHO, 2023.
• Organ involvement: Rarely, a drug rash may be a marker for drug‑induced hepatitis, nephritis, or eosinophilic pneumonia.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Adverse Drug Reactions: Epidemiology and Outcomes. 2023.
2. National Institutes of Health. Drug-Induced Skin Reactions. MedlinePlus; 2022.
3. Mayo Clinic. Patch Testing for Drug Allergies. 2022.
4. World Health Organization. Severe Cutaneous Adverse Reactions (SCARs) Report. 2023.

```